Heron Therapeutics Inc. (HRTX)
Heron Therapeutics Statistics
Share Statistics
Heron Therapeutics has 152.33M shares outstanding. The number of shares has increased by 1.11% in one year.
| Shares Outstanding | 152.33M |
| Shares Change (YoY) | 1.11% |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | 75.22% |
| Shares Floating | 151M |
| Failed to Deliver (FTD) Shares | 22.01K |
| FTD / Avg. Volume | 1.25% |
Short Selling Information
The latest short interest is 31.06M, so 20.42% of the outstanding shares have been sold short.
| Short Interest | 31.06M |
| Short % of Shares Out | 20.42% |
| Short % of Float | 20.57% |
| Short Ratio (days to cover) | 18.24 |
Valuation Ratios
The PE ratio is -17.18 and the forward PE ratio is -72. Heron Therapeutics's PEG ratio is 0.19.
| PE Ratio | -17.18 |
| Forward PE | -72 |
| PS Ratio | 1.62 |
| Forward PS | 1.1 |
| PB Ratio | -6.93 |
| P/FCF Ratio | -9.62 |
| PEG Ratio | 0.19 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Heron Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of -5.28.
| Current Ratio | 2.29 |
| Quick Ratio | 1.7 |
| Debt / Equity | -5.28 |
| Debt / EBITDA | -35.16 |
| Debt / FCF | -7.33 |
| Interest Coverage | -1.91 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.18M |
| Profits Per Employee | $-111.31K |
| Employee Count | 122 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.73 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -17.25% in the last 52 weeks. The beta is 1.55, so Heron Therapeutics's price volatility has been higher than the market average.
| Beta | 1.55 |
| 52-Week Price Change | -17.25% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 2.06 |
| Relative Strength Index (RSI) | 44.61 |
| Average Volume (20 Days) | 1.76M |
Income Statement
In the last 12 months, Heron Therapeutics had revenue of 144.28M and earned -13.58M in profits. Earnings per share was -0.09.
| Revenue | 144.28M |
| Gross Profit | 105.64M |
| Operating Income | -11.53M |
| Net Income | -13.58M |
| EBITDA | -5.06M |
| EBIT | -7.55M |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 25.8M in cash and 177.76M in debt, giving a net cash position of -151.96M.
| Cash & Cash Equivalents | 25.8M |
| Total Debt | 177.76M |
| Net Cash | -151.96M |
| Retained Earnings | -1.92B |
| Total Assets | 233.15M |
| Working Capital | 117.56M |
Cash Flow
In the last 12 months, operating cash flow was -22.53M and capital expenditures -1.71M, giving a free cash flow of -24.23M.
| Operating Cash Flow | -22.53M |
| Capital Expenditures | -1.71M |
| Free Cash Flow | -24.23M |
| FCF Per Share | -0.16 |
Margins
Gross margin is 73.21%, with operating and profit margins of -7.99% and -9.41%.
| Gross Margin | 73.21% |
| Operating Margin | -7.99% |
| Pretax Margin | -9.41% |
| Profit Margin | -9.41% |
| EBITDA Margin | -3.5% |
| EBIT Margin | -7.99% |
| FCF Margin | -16.8% |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for HRTX is $6, which is 184.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 184.4% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jan 13, 2014. It was a backward split with a ratio of 1:20.
| Last Split Date | Jan 13, 2014 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -9.62 |
| Piotroski F-Score | 2 |